The Mentor Capital Cancer Immunotherapy Index ^©

* Cancer Immunotherapy Index developed with Mike Havrilla, PhD., Editor of BioMedReports.com, as a sub-set to his Cancer Diagnostic & Therapeutic Micro-Cap Index.
** 33.3% gain reflects MNTR private bids at $16 and matches corresponding 33.66% gain by MNTR during 22 week period in which MNTR substantially held only QI.
*** Market Data from National Cancer Institute based on Relative Mortality in company treatment areas & 50% penetration by immunotherapy sector into cancer treatments.

NO INVESTMENT ADVISORY DISCLAIMER: Readers are cautioned that Mentor Capital, Inc. does not intend this Cancer Immunotherapy Index to be investment advice. The CI Index is an mathematical, information only index and has been published on a regular weekly basis since inception. The original and continuing purpose is to establish a benchmark as to how the cancer immunotherapy sector as a whole has behaved. As such, it presents historic information and does not purport nor imply any opinion or advice on the current or future value of any stock, nor account for trading costs that in practice will reduce investment gains. Always consult with your investment advisor before buying MNTR or CI Index stocks.